BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29164770)

  • 1. Clinical outcomes of patients with coronary artery aneurysm after the first generation drug-eluting stent implantation.
    Joo HJ; Woong Yu C; Choi R; Park J; Lee HJ; Kim JS; Choi YJ; Park JH; Hong SJ; Lim DS
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):E235-E245. PubMed ID: 29164770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary Artery Aneurysm after Second-Generation Drug-Eluting Stent Implantation.
    Hong SJ; Kim H; Ahn CM; Kim JS; Kim BK; Ko YG; Hong BK; Choi D; Jang Y; Hong MK
    Yonsei Med J; 2019 Sep; 60(9):824-831. PubMed ID: 31433580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ultra-long second-generation drug-eluting stent implantation.
    Honda Y; Muramatsu T; Ito Y; Sakai T; Hirano K; Yamawaki M; Araki M; Kobayashi N; Takimura H; Sakamoto Y; Mouri S; Tsutumi M; Takama T; Takafuji H; Tokuda T; Makino K
    Catheter Cardiovasc Interv; 2016 Feb; 87(2):E44-53. PubMed ID: 26010548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
    Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II.
    Jang WJ; Ahn SG; Song YB; Choi SH; Chun WJ; Oh JH; Cho SW; Kim BS; Yoon JH; Koo BK; Yu CW; Jang YS; Tahk SJ; Kim HS; Gwon HC; Lee SY; Hahn JY
    Circ Cardiovasc Interv; 2018 Jul; 11(7):e005849. PubMed ID: 30006330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes of Biodegradable Versus Second-Generation Durable Polymer Drug-Eluting Stent Implantations for Myocardial Infarction.
    Choe JC; Cha KS; Lee JG; Kim J; Shin JY; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    JACC Cardiovasc Interv; 2020 Jan; 13(1):97-111. PubMed ID: 31918948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Clinical Outcomes and Optimal Stent Strategy in Left Main Coronary Bifurcation Stenting.
    Cho S; Kang TS; Kim JS; Hong SJ; Shin DH; Ahn CM; Kim BK; Ko YG; Choi D; Song YB; Hahn JY; Choi SH; Gwon HC; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2018 Jul; 11(13):1247-1258. PubMed ID: 29976361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial.
    Roguin A; Camenzind E; Kerner A; Beyar R; Boersma E; Mauri L; Steg PG; Wijns W
    JACC Cardiovasc Interv; 2017 Mar; 10(6):548-556. PubMed ID: 28335893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M; Pross V; Marx N; Hoffmann R
    Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.